Westin Discusses Insights From the DUO-E Trial in Endometrial Cancer

Shannon Westin, MD, MPH, FACOG, director, Early Drug Development, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses her hopes following the presentation of promising data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial (NCT04269200) of durvalumab (Imfinzi) plus chemotherapy followed by durvalumab and olaparib (Lynparza) maintenance in patients with newly diagnosed advanced or recurrent endometrial cancer.

At the ESMO 2023 Congress, Westin presented the primary analysis of progression-free survival (PFS) and the first pre-planned interim analysis of overall survival.

According to Westin, the combination of immunotherapy with chemotherapy shows promise for patients with advanced endometrial cancer and can better outcomes. Findings showed that the benefit of PFS was greatest in patients with mismatch repair-deficient disease treated with durvalumab, and the addition of olaparib to durvalumab maintenance therapy improved PFS in patients who were mismatch repair-proficient and those positive for PD-L1.

Transcription:

0:10 | While I am hopeful that we will soon see this available for our patients on a day to day basis, I think the mismatch repair-deficient group, we know we need to give checkpoint with chemotherapy followed by checkpoint maintenance, and so that is what we should be doing.

0:22 | Now for this mismatch repair-proficient group, we really can be considering the addition, not only of the durvalumab to chemotherapy, but then that follow-up of durvalumab and olaparib maintenance to help patients live longer without their cancer coming back.

0:36 | Now, there's a lot of interests in teasing out molecular subtypes and understanding, can we parse out even more who truly benefits and I'm 100% behind that, but those are going to be exploratory analyses. And the bottom line is our primary analysis was positive, and that combination does work more than control arm of chemotherapy.